Contact information
Colleges
Dr Charlotte Brierley
MA, BM BCh, MRCP, DPhil
Academic Clinical Lecturer in Haematology
Investigating the cellular and genetic landscape of myeloid neoplasms
I recently completed my Wellcome Trust Clinical Research Fellowship in the haematopoietic stem cell biology group supervised by Prof Adam Mead and Dr Bethan Psaila. This time was shaped by a visiting fellowship to Dr Elli Papaemmanuil’s group at Memorial Sloan Kettering Cancer Centre in New York. My project focused on using single cell approaches to understand the genomic, proteomic and transcriptomic changes in blast-phase myeloproliferative neoplasms, a particularly aggressive type of AML.
Prior to this, I completed my undergraduate degree in medical sciences at the University of Cambridge and subsequent clinical medical training at Oxford. After qualifying I was awarded an NIHR Academic Foundation post in Edinburgh, after which I returned to Oxford as an Academic Clinical Fellow.
I am now an Academic Clinical Lecturer here in Oxford, which allows me to combine completion of my clinical training in haematology with academia. My research aims to understand how patients with acute myeloid leukaemia (AML) develop the disease, and why some respond to treatment better than others. We hope that understanding the mechanisms of disease development, progression and response to therapy will lead to the identification of novel therapeutic targets to help patients with this disease.
Recent publications
-
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.
Journal article
Brierley CK. et al, (2023), bioRxiv
-
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution.
Journal article
Rodriguez-Meira A. et al, (2023), Nat Genet, 55, 1531 - 1541
-
A tale of two alleles: TP53 and transformation in MPNs.
Journal article
Brierley C. and Psaila B., (2022), Blood, 139, 3567 - 3568
-
Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms
Conference paper
Li R. et al, (2022), BLOOD, 140, 1091 - 1092
-
Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN
Conference paper
Brierley CK. et al, (2020), BLOOD, 136